The
global erectile dysfunction drugs market was valued at USD 4.3
billion in 2012 and is expected to decline at a CAGR of (4.5%) from
2013 to 2019, to reach an estimated value of USD 3.4 billion in 2019.
Browse
the full report with complete TOC at Erectile Dysfunction
Drugs Market
http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html
Erectile
dysfunction is the inability to attain or maintain penile erection in
men, sufficient for successful sexual intercourse. Erectile
dysfunction is a common medical disorder primarily affecting men
older than 40 years of age. In addition, other than the typical
causes of erectile dysfunction, such as diabetes and hypertension, a
number of common lifestyle related factors are also associated with
development of the condition. These include obesity, excessive
alcohol consumption, smoking, use of recreational drugs, and poor
physical and psychological health. Commonly, oral drugs belonging to
the PDE 5 inhibitors class form the mainstay of erectile dysfunction
treatment. Other treatment options include lifestyle modification,
testosterone therapy, penile devices, injection therapies and
psychotherapy.
The
global market for erectile dysfunction drugs has been studied from
the perspective of currently marketed branded drugs and pipeline
drugs. Branded drugs include Viagra (sildenafil citrate), Cialis
(tadalafil), Levitra/Staxyn (vardenafil), Stendra/Spedra (avanafil),
Zydena (udenafil), MUSE (medicated urethral systems for erection),
Mvix (mirodenafil) and Helleva (lodenafil). The drugs in the pipeline
for erectile dysfunction treatment primarily consist of two major
drugs, namely Vitaros (alprostadil) and Uprima (apomorphine)
currently in later phases of clinical trials.
In
2012, Viagra (sildenafil citrate) accounted for the largest share
(45%) by revenue of the total erectile dysfunction drugs market.
However, due to the loss of the drug's patent exclusivity in Europe
and other countries in 2013, the overall market revenue is expected
to decline during the forecast period as international markets
contribute considerably to the overall market revenue of the drug. In
the U.S. market, Viagra will continue to maintain a major revenue
share due to its extended patent exclusivity till 2020. The market
for Cialis (tadalafil) accounted for the second largest share at USD
1,926.8 million, in 2012. However, it is expected to witness a
decline in market revenue at a CAGR of (12.6%) from 2013 to 2019,
owing to loss of patent exclusivity in 2017. In addition, the patent
for Bayer's Levitra/Staxyn (vardenafil) is scheduled to expire in
2018 and is thus expected to contribute to the declining market
revenue.
Request
for customization of this report
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1550
A
few novel compounds are currently under investigation in both
preclinical and clinical settings, for the treatment of impotency.
These studies are majorly focused on medications with improved
efficacy, shorter onset of action and fewer side effects as compared
to the currently available treatments. Such pipeline drugs include
Vitaros (alprostadil), Uprima (apomorphine) and Topiglan
(alprostadil), amongst others.
Geographically,
North America dominated the global market for erectile dysfunction
drugs in terms of revenue generation and is expected to maintain its
position throughout the forecast period. The extended patent
exclusivity for Pfizer's Viagra (sildenafil citrate) in the U.S.,
till 2020, will be responsible for the leadership of the North
American market. Europe was the second largest regional market for
erectile dysfunction drugs in 2012, owing to the increased demand for
ED drugs. Market growth will also be facilitated by the expected
marketing approvals for a few promising drug candidates such as
Stendra/Spedra (avanafil) and Zydena (udenafil) by mid 2014.
Browse
all Press Releases:
http://www.transparencymarketresearch.com/press-releases.htm
The
global erectile dysfunction dugs market is dominated by few major
players including Pfizer, Inc. Eli Lilly & Co., and Bayer AG.
Post patent expiration of the major branded drugs and intense
genericization of the market, the competition in this market is
expected to be characterized by consolidation activities,
partnerships, and intensive mergers and acquisitions. The other key
players in the erectile dysfunction drugs market include Dong-A
Pharmaceutical Co. Ltd., Vivus, Inc., Apricus Biosciences, Inc. and
Meda Pharmaceuticals.
Browse
all Article :
http://www.transparencymarketresearch.com/articles.htm
The
global erectile dysfunction drugs market is segmented as follows:
Erectile
Dysfunction Drugs Market, by Major Branded Products
Viagra
Cialis
Levitra/Staxyn
Stendra/Spedra
Zydena
MUSE
Mvix
Helleva
Erectile
Dysfunction Drugs Market, Pipeline Analysis
Vitaros
Uprima
Others
Topiglan
Melanocortin
Activators
Gene
Therapy
Erectile
Dysfunction Drugs Market, by Geography
North
America
Europe
Asia-Pacific
Rest
of the World (RoW)
Browse
all Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are
privileged with highly experienced team of Analysts, Researchers, and
Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Sheela
AK
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Web:
http://www.transparencymarketresearch.com/
Blog:
http://www.tmrblog.com/
No comments:
Post a Comment